MX2023010424A - Degradadores bifuncionales de inmunoglobulina deficientes en galactosa. - Google Patents

Degradadores bifuncionales de inmunoglobulina deficientes en galactosa.

Info

Publication number
MX2023010424A
MX2023010424A MX2023010424A MX2023010424A MX2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A MX 2023010424 A MX2023010424 A MX 2023010424A
Authority
MX
Mexico
Prior art keywords
immunoglobulins
galactose
deficient
moiety
glycan
Prior art date
Application number
MX2023010424A
Other languages
English (en)
Spanish (es)
Inventor
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2023010424A publication Critical patent/MX2023010424A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023010424A 2021-03-10 2022-03-10 Degradadores bifuncionales de inmunoglobulina deficientes en galactosa. MX2023010424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
MX2023010424A true MX2023010424A (es) 2023-09-18

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010424A MX2023010424A (es) 2021-03-10 2022-03-10 Degradadores bifuncionales de inmunoglobulina deficientes en galactosa.

Country Status (11)

Country Link
US (1) US20240309114A1 (https=)
EP (1) EP4304579A1 (https=)
JP (1) JP2024509282A (https=)
KR (1) KR20230154900A (https=)
CN (1) CN116997337A (https=)
AU (1) AU2022232620A1 (https=)
BR (1) BR112023017702A2 (https=)
CA (1) CA3211335A1 (https=)
IL (1) IL305665A (https=)
MX (1) MX2023010424A (https=)
WO (1) WO2022192478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013274A (es) * 2021-05-17 2023-11-30 Biohaven Therapeutics Ltd Composiciones que incluyen potenciadores de tratamientos conjugados.
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2024228935A1 (en) * 2023-04-29 2024-11-07 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
SG11201606761RA (en) * 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
PL3145934T3 (pl) * 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

Also Published As

Publication number Publication date
US20240309114A1 (en) 2024-09-19
WO2022192478A1 (en) 2022-09-15
EP4304579A1 (en) 2024-01-17
KR20230154900A (ko) 2023-11-09
CA3211335A1 (en) 2022-09-15
IL305665A (en) 2023-11-01
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
AU2022232620A1 (en) 2023-09-21
CN116997337A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
MX2023010424A (es) Degradadores bifuncionales de inmunoglobulina deficientes en galactosa.
MX2025012882A (es) Degradadores bifuncionales de inmunoglobulinas deficientes en galactosa
MX2023008000A (es) Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
EP3941945A4 (en) ANTITROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF
WO2002064634A3 (en) Human monoclonal antibodies to fc alpha receptor (cd89)
MX2022016180A (es) Conjugados anticuerpo-fármaco que comprenden anticuerpos anti-b7-h3.
SG10201810743WA (en) Conjugation methods
WO2018151817A8 (en) Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders
WO2020172528A8 (en) Albumin binding antibodies and use thereof
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
RU2016111137A (ru) Сконструированные конъюгаты против dll3 и способы применения
MX2023004434A (es) Anticuerpos anti-fgfr2 y metodos para usarlos.
JP2018537410A5 (https=)
NO20072670L (no) PLAD domene peptider med okt halveringstid i serum pa grunn av konjugering til domene antistoffer
WO2019215510A3 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
TW200607523A (en) Drug compositions, fusions and conjugates
MX2022010599A (es) Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
MX2023010099A (es) Enlazadores ramificados para conjugados de anticuerpo-fármaco y métodos de uso de estos.
PH12022551000A1 (en) Directed conjugation technologies
WO1998023646A3 (en) Binding agents specific for IGA receptor
MY199140A (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
WO2006073493A3 (en) Vaccine conjugates comprising a monoclonal antibody binding to human dentritic cells and beta human chronic gonadotropin
DE69726674D1 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
WO2009132081A3 (en) Monoclonal antibody-based targeting of folate receptors